-(-)Gossypol promotes the apoptosis of bladder cancer cells in vitro

Pharmacological Research

Volumn 58, Issue 5-6, 2008, Pages 323-331

  Macoska, Jill A ^a   Adsule, Shreelekha ^a   Tantivejkul, Kwanchanit ^b   Wang, Shaomeng ^b   Pienta, Kenneth J ^b   Lee, Cheryl T ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

( )Gossypol; Apoptosis; Bladder cancer; Chemotherapy

Indexed keywords

BH3 PROTEIN; BIM PROTEIN; CARBOPLATIN; CASPASE 3; GEMCITABINE; GOSSYPOL; PACLITAXEL; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MCL 1; PUMA PROTEIN; TUBULIN;

APOPTOSIS; ARTICLE; BLADDER CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CELL PROLIFERATION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DNA DAMAGE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VITRO STUDY; MONOTHERAPY; PRIORITY JOURNAL; PROTEIN ANALYSIS; TRANSITIONAL CELL CARCINOMA;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BLOTTING, WESTERN; CARBOPLATIN; CELL LINE, TUMOR; CELL PROLIFERATION; DEOXYCYTIDINE; GENES, BCL-2; GOSSYPOL; HUMANS; PACLITAXEL; URINARY BLADDER NEOPLASMS;

EID: 56649095807     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2008.09.005     Document Type: Article

References (49)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., et al. CA Cancer J Clin 58 March-April (2) (2008) 71-96 [Epub 2008 February 20. Cancer statistics, 2008]
2. Rosenburg J.E., Carrol P.R., and Small E.J. Update on chemotherapy for advanced bladder cancer. J Urol 174 1 (2005) 14-20
3. Gallagher S.D.J., Milowsky M.I., and Bajorin D.F. Advanced bladder cancer: status of first-line chemotherapy and the search for active agents in the second-line setting. Cancer July (2008) [Epub ahead of print]
4. Cory S., and Adams J.M. The Bcl2 family: regulators of the cellular life or death switch. Nat Rev Cancer 2 9 (2002) 647-656
5. Adams J.M., and Cory S. The Bcl2 apoptotic switch in cancer development and therapy. Oncogene 26 (2007) 1324-1337
6. Krish E.J., Baunnoch D.A., and Stadler W.M. Expression of Bcl2 and Bcl-x in bladder cancer. J Urol 159 4 (1998) 1348-1353
7. Miyake H., Hanada N., Nakamura H., Kagawa S., Fujiwara T., Hara I., et al. Overexpression of Bcl2 in bladder cancer cells inhibits apoptosis induced by cisplatin and adenoviral mediated p53 gene transfer. Oncogene 1916 7 (1998) 933-943
8. Hussain S.A., Jarensen R., Hiller L., Cooke P.W., Murray P., Young L.S., et al. Bcl2 expression predicts survival in patients receiving systemic chemotherapy in advanced TCC of bladder. Oncol Rep 10 3 (2003) 571-576
9. Pollack A., Wu C.S., Czemiak B., Zagars G.K., Benedict W.F., and Mcdonnell T.J. Abnormal Bcl2 and pRB expression are independent correlates of radiation response in muscle invasive bladder cancer. Uri Ca Res 3 10 (1997) 1823-1829
10. Coutinho E.M. Gossypol: a contraceptive for men. Contraception 65 4 (2002) 259-263
11. Cui G.H., Xu Z.L., Yang Z.J., Xu Y.Y., and Xue S.P. A combined regimen of gossypol plus methyltestesterone and ethinylestradiol as a contraceptive induces germ cell apoptosis and expression of its related genes in rats. Contraception 70 4 (2004) 335-342
12. Bauer J.A., Trash D.K., Kumar B., Los G., Castro J., Lee J.S., et al. Reversal of cisplatin resistance with BH3 mimetic -(-)gossypol in Head & Neck cancer cells: role of wild type p53 and Bcl-xL. Mol Cancer Ther 4 7 (2005) 1096-1104
13. Oliver C.L., Bauer J.A., Wolter K.A., Ubell M.L., Narayan A., O'connell K.M., et al. In vitro effects of BH3 mimetic, -(-)gossypol, on head and neck squamous cell carcinoma cells. Clin Can Res 1510 22 (2004) 7757-7763
14. Zhang M., Liu H., Tian Z., Griffith B., Ji M., and Li Q. Gossypol induces apoptosis in human PC3 prostate cancer cells by modulating caspase-dependent and caspase independent cell death pathways. Life Sci 80 (2007) 767-774
15. Mohammad R.M., Wang S., Banerjee S., Wu X., Chen J., and Sarkar F.H. Non-peptidic small molecule inhibitor of Bcl2 and Bcl-xL,-(-)Gossypol, enhances biological effects of genistein against BxPC3 pancreatic cancer cell line. Pancreas 31 4 (2005) 317-324
16. Zhang M., Liu H., Guo R., Ling Y., Wu X., Li B., et al. Molecular mechanism of Gossypol induced cell growth inhibition and cell death of HT-29 human colon carcinoma cells. Biochem Pharmacol 66 1 (2003) 93-103
17. Wang G., Nikoloska-Coleska Z., Yang C.Y., Wang R., Tang R., Guo J., et al. Structure based design of potent small molecule inhibitor of anti apoptotic Bcl2 protein. J Med Chem 49 (2006) 6139-6142
18. Degtrev A., Lugovsky A., Cardone M., Mulley B., Way S., Wagner G., et al. Identification of small molecule inhibitors of interaction between the BH3 domain and Bcl-xL. Nat Cell Biol 3 2 (2001) 173-183
19. Flack M.R., Pyle R.G., and Mullen N.M. Oral gossypol in the treatment of metastatic adrenal cancer. J Clin Endocrinol Metab 76 (1994) 1019-1024
20. Van Poznak C., Seidman A.D., and Reidenberg M.M. Oral gossypol in the treatment of patients with refractory metastatic breast cancer: a phase I/II clinical trial. Breast Cancer Res Treat 66 (2001) 239-248
21. Shinohara N., Liebert M., Wedemeyer G., Chang J.H., and Grossman H.B. Evaluation of multiple drug resistance in human bladder cancer cell lines. J Urol 150 August (2 Pt 1) (1993) 505-509
22. Sabichi A., Keyhani A., Tanaka N., Delacerda J., Lee I.L., Zou C., et al. Characterization of a panel of cell lines derived from urothelial neoplasms: genetic alterations, growth in vivo and the relationship of adenoviral mediated gene transfer to coxsackie adenovirus receptor expression. J Urol 175 March (3 Pt 1) (2006) 1133-1137
23. Begley L., Monteleon C., Shah R.B., Macdonald J.W., and Macoska J.A. CXCL12 overexpression and secretion by aging fibroblasts enhance human prostate epithelial proliferation in vitro. Aging Cell 4 December (6) (2005) 291-298
24. Begley L.A., MacDonald J.W., Day M.L., and Macoska J.A. CXCL12 activates a robust transcriptional response in human prostate epithelial cells. J Biol Chem 282 September (37) (2007) 26767-26774 [Epub 2007 July 12]
25. Hong J.H., Lee E., Hong J., Shin Y.J., and Ahn H. Antisense Bcl2 oligonucleotide in cisplatin-resistant bladder cancer cell lines. BJU Int 90 July (1) (2002) 113-117
26. Lebedeva I., Raffo A., Rando R., Ojwang J., Cossum P., and Stein C.A. Chemosensitization of bladder carcinoma cells by bcl-xL antisense oligonucleotides. J Urol 166 August (2) (2001) 461-469
27. van Delft M.F., Wei A.H., Mason K.D., Vandenburg C.J., Chen L., Czabator P.E., et al. The BH3 mimetic ABT-737 targets selective Bcl2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 10 (2006) 389-399
28. Chen L., Willis S.N., Smith B.J., Fletcher J.L., Hinds M.G., Colman P.M., et al. Differential targeting of prosurvival Bcl2 proteins by their BH3 only ligands allows complementary apoptotic function. Mol Cell 417 3 (2005) 393-403
29. Philchenkov A. Caspases: potential targets for regulating cell death. J Cell Mol Med 8 4 (2004) 432-444
30. Parekh D.J., Bochner B.H., and Dalbagni G. Superficial and muscle-invasive bladder cancer: principles of management for outcomes assessments. J Clin Oncol 24 December (35) (2006) 5519-5527
31. Mitra A., Datar R.H., and Cote R.J. Molecular pathways in Invasive Bladder Cancer: new insights into mechanisms, progression and target identification. J Clin Oncol 24 35 (2006) 5552-5563
32. Hussain M., Vaishampayan U., Du W., Redman B., and Smith D. Combination Paclitaxel, carboplatin and gemcitabine is an active treatment for advanced urothelial cancers. JCO 19 9 (2001) 2527-2533
33. Kilani R.T., Tamimi Y., and Kamala S. Selective cytotoxicity of gemcitabine in bladder cancer cell lines. Anticancer Drugs 13 (2002) 557-566
34. Stadler W.M., Kuzel T., Roth B., Raghavan, and Dorr F.A. Phase II study of single agent gemcitaine in previously untreated patients with metastatic urothelial cancers. JCO 15 (1997) 3394-3398
35. Moore M.J., Tannock I.F., Ernst D.S., Huan S., and Murray N. Gemcitabine: promising new agent in the treatment of advanced urothelial cancer. JCO 15 12 (1997) 3441-3445
36. Loehrer P.J., Einhorn L.H., Elson P.J., Crawford E.D., Kuebler P., Tannock L., et al. A randomized comparison of cisplatin alone or in combination with methotraxate, vinblastine and doxorubicin in patients with metastatic uorthelial carcinoma: a cooperative group study. JCO 10 7 (1992) 1066-1073
37. Logothetis C.J., Dexeus F.H., and Finn L. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. JCO 8 6 (1990) 1050-1055
38. Waxman J., and Barton C. Carboplatin-based chemotherapy for bladder cancer. Cancer Treat Rev 19 (1993) 21-25
39. Roth B.J., Dreicer R., and Einhorn L.H. Significant activity of paclitaxel in advanced transitional cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group. J Clin Oncol 12 (1994) 2264-2270
40. Vaughn D.J. Moving forward in advanced bladder cancer. JCO 25 16 (2007) 2162-2163
41. Chresta C.M., Arriole F.L., and Hichman J.A. Apoptosis and Cancer chemotherapy. Behring Inst Mitt 97 (1996) 232-240
42. Hussain S.A., Ganesan R., Hiller L., Cooke P.W., Murray P., Young L.S., et al. Bcl2 expression predicts survival in patients receiving synchronous chemoradiotherapy in advanced transitioinal cell carcinoma of the bladder. Oncol Rep 10 3 (2003) 571-576
43. Duggan B., Kelly J., Keane P.F., Williamson K., and Johnston S.R. Bcl2 expression identifies patients with advanced bladder cancer treated by radiotherapy who benefit from neoadjuvant chemotherapy. BJU 86 6 (2000) 757-1757
44. Maluf F.C., Corcon-Cardo C., Verbal D.A., satagopan J.M., Boyle M.G., Herr H., et al. Assessing interaction between MDM2, p53, Bcl2 as prognostic variables in muscle invasive Bladder cancer treated with neo-adjuvant chemotherapy followed by locoregional surgical treatment. Ann Oncol 17 11 (2006) 1677-1686
45. Willis S.N., Chen L., Dewson G., Wei A., Naik E., Fletcher J.L., et al. Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xl, but not Bcl2, until displaced by BH3 only proteins. Genes Dev 19 11 (2005) 1294-1305
46. Youle R.J., and Strasser A. The Bcl2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 9 (2008) 47-59
47. Hong J.H., Lee E., Hong J., Shin Y.J., and Ahn H. Antisense Bcl2 oligonucleotide in cisplatin resistant bladder cancer cell lines. BJU Int 90 1 (2002) 113-117
48. Agarwal P.K., Blaeh P.C., McConkey D.J., and Dinney C.D. Emerging drugs for targeted therapy of Bladder cancer. Exp Opin Emerg Drugs 12 3 (2007) 435-448
49. Labi V., Grespi F., Baumgartner F., and Villunger A. Targeting the Bcl-2-regulated apoptosis pathway by BH3 mimetics: a breakthrough in anticancer therapy?. Cell Death Differ 15 June (6) (2008) 977-987 [Epub 2008 March 28]